The FDA has granted breakthrough therapy status to Boehringer Ingelheim’s nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis.

IPF is a serious and life-threatening lung disease that causes permanent scarring of the lungs, difficulty breathing and decreases the amount of oxygen the lungs can supply to the body. IPF affects as many as 132,000 Americans. There are currently no FDA-approved treatments.